TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24912589

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 11,629) received screening, risk assessment, and lifestyle counselling up to four times over five years.
Number of subjects: 59616

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 11,629) received lifestyle counselling.
Number of subjects: 59616

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 11,629) received combined lifestyle intervention.
Number of subjects: 59616

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 11,629) received lifestyle intervention.
Number of subjects: 59616
Study: 22354743

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation (20,000 IU weekly)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 20207618

Group type: EXPERIMENTAL
Intervention: Dermacyn(R) Wound Care (DWC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Povidone iodine
Number of subjects: 40
Study: 18030230

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg daily for 12 months)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg daily for 12 months) + Vitamin D2 (50,000 IU monthly for 6 months)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 72
Study: 16219012

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg qd
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg qd
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 12802214

Group type: EXPERIMENTAL
Intervention: Pharmaceutical treatment for chronic illnesses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmaceutical treatment
Number of subjects: 0
Study: 10778797

Group type: EXPERIMENTAL
Intervention: Aquatic therapy (water) at 30 degrees/s
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dry land therapy at 30 degrees/s
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aquatic therapy (water) at 45 degrees/s
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dry land therapy at 45 degrees/s
Number of subjects: 6
Study: 8879718

Group type: EXPERIMENTAL
Intervention: Effective forms of ECT
Number of subjects: 143

Group type: COMPARATOR
Intervention: Ineffective forms of ECT
Number of subjects: 143
Study: 1537520

Group type: EXPERIMENTAL
Intervention: Erythromycin 200 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 6370811

Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 35
Study: 30105847

Group type: EXPERIMENTAL
Intervention: Topical liposomal hydroquinone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional hydroquinone
Number of subjects: 20
Study: 27778161

Group type: EXPERIMENTAL
Intervention: Action Observation Training (AOT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Landscape (control group)
Number of subjects: 25
Study: 24957562

Group type: EXPERIMENTAL
Intervention: Non-forensic family assessment (experimental group)
Number of subjects: 4629

Group type: COMPARATOR
Intervention: Forensic investigation (control group)
Number of subjects: 4629
Study: 25379688

Group type: EXPERIMENTAL
Intervention: Active supplement (500 mg olive leaf extract, 100 mg green coffee bean extract, 150 mg beet powder)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 22546837

Group type: EXPERIMENTAL
Intervention: Docetaxel (T) 75 mg/m² on day 1 of a 21-day cycle for six cycles
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no docetaxel)
Number of subjects: 100
Study: 19046909

Group type: EXPERIMENTAL
Intervention: rhIGF‐I (50 microg/kg, four days/week)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 17321927

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (nonstimulation group)
Number of subjects: 40
Study: 15138163

Group type: EXPERIMENTAL
Intervention: Corticosteroids plus daclizumab (1 mg/kg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Corticosteroids (2 mg/kg)
Number of subjects: 102
Study: 15257932

Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation (performed in 47 patients with a donor)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Autologous transplantation or maintenance chemotherapy (given to 84 patients without a sibling donor)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation (with donor)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Autologous transplantation or maintenance chemotherapy (without donor)
Number of subjects: 279
Study: 10333984

Group type: EXPERIMENTAL
Intervention: Befloxatone (up to 160 mg single dose or 80 mg/day for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Befloxatone (up to 20 mg once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Befloxatone (10 mg dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Befloxatone (various doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Befloxatone
Number of subjects: 0
Study: 8024805

Group type: EXPERIMENTAL
Intervention: Calcipotriol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednicarbate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clobetasol 17-propionate
Number of subjects: 0
Study: 2654849

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (7.9 +/- 0.4 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 10
Study: 616218

Group type: EXPERIMENTAL
Intervention: CO breathing (increased COHb saturation)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Air breathing (control)
Number of subjects: 44
Study: 30590827

Group type: EXPERIMENTAL
Intervention: New Nordic Renal Diet (NNRD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 18
Study: 28369530

Group type: EXPERIMENTAL
Intervention: Moxidectin (8 mg)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Ivermectin (200 μg/kg)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Moxidectin
Number of subjects: 127

Group type: COMPARATOR
Intervention: Ivermectin
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Moxidectin and Ivermectin
Number of subjects: 127
Study: 25700320

Group type: EXPERIMENTAL
Intervention: Denture adhesives (DA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Denture adhesives (DA) in glue form
Number of subjects: 60
Study: 24485039

Group type: EXPERIMENTAL
Intervention: Intracranial pressure (ICP) monitoring
Number of subjects: 324

Group type: COMPARATOR
Intervention: Clinical exam-based monitoring
Number of subjects: 324
Study: 20884178

Group type: EXPERIMENTAL
Intervention: Waon therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 54
Study: 19148629

Group type: EXPERIMENTAL
Intervention: Test formulation of DHA/EPA (3.0 g/day, t.i.d. for 28 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference formulation of DHA/EPA (3.0 g/day, t.i.d. for 28 days)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 48
Study: 17529899

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) 720 mg twice a day
Number of subjects: 88

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 1000 mg twice a day
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 88
Study: 15061265

Group type: EXPERIMENTAL
Intervention: Dopaminergic and non-dopaminergic treatment (off-medication)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 14
Study: 11447960

Group type: EXPERIMENTAL
Intervention: Fluoride-releasing resin composite (Light Bond)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (Fuji Ortho LC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-fluoride-releasing resin composite (Concise)
Number of subjects: 45
Study: 9493577

Group type: EXPERIMENTAL
Intervention: 1 l gelatin‐based plasma substitute (Gelofusine)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0.9% NaCl (control)
Number of subjects: 6
Study: 8043455

Group type: EXPERIMENTAL
Intervention: Vinblastine slow infusion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vinblastine bolus injection
Number of subjects: 42
Study: 1818430

Group type: EXPERIMENTAL
Intervention: Klion ointment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (another method)
Number of subjects: 28
Study: 76857

Group type: EXPERIMENTAL
Intervention: Injection/compression sclerotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 100
Study: 30901716

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise programme
Number of subjects: 120

Group type: COMPARATOR
Intervention: Health education programme (control)
Number of subjects: 120
Study: 27935240

Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 25452012

Group type: EXPERIMENTAL
Intervention: Spinal stenosis pedometer and nutrition lifestyle intervention (12 weeks)
Number of subjects: 10
Study: 23566446

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 478

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 478
Study: 21806517

Group type: EXPERIMENTAL
Intervention: Two or four counselling sessions involving cognitive behaviour therapy and motivational interviewing techniques to manage methamphetamine use.
Number of subjects: 214

Group type: COMPARATOR
Intervention: Self-help booklet (control group).
Number of subjects: 214
Study: 19013544

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia (FiO(2): 0.15-0.12)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normoxia (control)
Number of subjects: 18
Study: 18257156

Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy with sparfloxacine and vibromagnetolaser therapy (VMLG‐10 unit)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Antimicrobial therapy with sparfloxacine and 10 sessions of manual massage
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Vibromagnetolaser therapy (VMLG‐10 unit)
Number of subjects: 49
Study: 15142009

Group type: EXPERIMENTAL
Intervention: Bench press exercise at 60% 1RM
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bench press exercise at 80% 1RM
Number of subjects: 28
Study: 11187872

Group type: EXPERIMENTAL
Intervention: High-dose FVIII regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose FVIII regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bypass therapy (on demand)
Number of subjects: 0
Study: 9183060

Group type: EXPERIMENTAL
Intervention: Teeth with oil contamination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teeth with oil contamination but no prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no oil contamination)
Number of subjects: 0
Study: 8245359

Group type: EXPERIMENTAL
Intervention: Femoral vein contrast delivery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Upper extremity contrast delivery
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Precordial echocardiography with femoral vein contrast delivery
Number of subjects: 70
Study: 2581469

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine, 1:200 000 adrenaline and dextran 150
Number of subjects: 2

Group type: COMPARATOR
Intervention: 0.5% bupivacaine, 1:200 000 adrenaline and dextran 110
Number of subjects: 2
Study: 30678354

Group type: EXPERIMENTAL
Intervention: Moyo (continuous monitoring)
Number of subjects: 2973

Group type: COMPARATOR
Intervention: Doppler (intermittent monitoring)
Number of subjects: 2973
Study: 29770528

Group type: EXPERIMENTAL
Intervention: Pain at 1-week follow-up
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: STarT Back Screening Tool score (moderate or high)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Anticipated duration of LBP > 1 week
Number of subjects: 354

Group type: COMPARATOR
Intervention: Control for age, sex, and medication received
Number of subjects: 354
Study: 26872253

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Physical training (both types)
Number of subjects: 28
Study: 24326421

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE; 125 mg/wk) + Finasteride (5 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Testosterone enanthate (TE; 125 mg/wk)
Number of subjects: 60
Study: 22309826

Group type: EXPERIMENTAL
Intervention: MRI training
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Mock training
Number of subjects: 63

Group type: COMPARATOR
Intervention: Lab training
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: MRI and mock training
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Mock and MRI groups
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both days
Number of subjects: 63
Study: 21166272

Group type: EXPERIMENTAL
Intervention: Feedback-first group (n = 8)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Feedback-later group (n = 9)
Number of subjects: 17
Study: 17671006

Group type: EXPERIMENTAL
Intervention: Prospective randomized therapeutic trials
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oxford Levels of Evidence
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Modified Coleman Methodology Score
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CONSORT score
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Recruitment descriptions
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Power-level calculations
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Randomization
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Blinding
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Participant flow
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Follow-up, sample size, and blinding
Number of subjects: 54
Study: 15763716

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral (CB) intervention
Number of subjects: 56

Group type: COMPARATOR
Intervention: Low intensity comparison condition
Number of subjects: 56
Study: 11943947

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 16

Group type: COMPARATOR
Intervention: Famotidine
Number of subjects: 16
Study: 9463749

Group type: EXPERIMENTAL
Intervention: Measurement of urinary retinol-binding protein (RBP)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Measurement of beta-2-glycoprotein-1 (beta 2G1)
Number of subjects: 150
Study: 7623462

Group type: EXPERIMENTAL
Intervention: Moderate alcohol (mean blood alcohol concentration 0.043%)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low alcohol (mean blood alcohol concentration 0.011%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: No beverage (control session)
Number of subjects: 8
Study: 2201266

Group type: EXPERIMENTAL
Intervention: Artificial surfactant treatment
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control group (no surfactant treatment)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Both groups (treated and control)
Number of subjects: 231
Study: 195208

Group type: EXPERIMENTAL
Intervention: Adenine arabinoside (vidarabine)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 30921977

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided genicular nerve block
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fluoroscopy-guided genicular nerve block
Number of subjects: 80
Study: 28124224

Group type: EXPERIMENTAL
Intervention: TF-CBT
Number of subjects: 156

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 156
Study: 25627076

Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 40
Study: 23598724

Group type: EXPERIMENTAL
Intervention: Xylene exposure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (nonexposed participants)
Number of subjects: 30
Study: 22151512

Group type: EXPERIMENTAL
Intervention: Making a Difference! (MAD)
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Families Talking Together (FTT)
Number of subjects: 2016

Group type: EXPERIMENTAL
Intervention: Combined FTT+MAD intervention
Number of subjects: 2016
Study: 19152520

Group type: EXPERIMENTAL
Intervention: Intralesional injection of 5-aminolevulinic acid (ALA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (PDT)
Number of subjects: 0
Study: 17411413

Group type: EXPERIMENTAL
Intervention: Hospital-based syringe exchange program (SEP)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Community-based syringe exchange program (SEP)
Number of subjects: 166
Study: 16201049

Group type: EXPERIMENTAL
Intervention: Domestic fixed-dose combinations (rifampicin 120 mg, isoniazid 80 mg, pyrazinamide 250 mg for 2 months; rifampicin 300 mg, isoniazid 150 mg for 4 months)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Full 6-month standard regimens (2HRZE/4H3R3)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Domestic fixed-dose combinations
Number of subjects: 422

Group type: COMPARATOR
Intervention: Full 6-month standard regimens
Number of subjects: 422
Study: 11098962

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1-0.35 mg/kg/hr)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 2% Propofol (1.5-6 mg/kg/hr)
Number of subjects: 63

Group type: COMPARATOR
Intervention: 1% Propofol (retrospective comparison)
Number of subjects: 63

Group type: COMPARATOR
Intervention: 2% Propofol
Number of subjects: 63
Study: 9031577

Group type: EXPERIMENTAL
Intervention: Placebo administration during a 4-week double-blind and placebo-controlled study with a 2-week single-blind placebo lead-in period.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Inpatient milieu/structure (non-pharmacological intervention)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 8341050

Group type: EXPERIMENTAL
Intervention: Individually focused cognitive behavioral (CB) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relationship enhancement (RE) of brief cognitive behavioral treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing alcohol-specific support
Number of subjects: 0
Study: 3330184

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 75 mg amitriptyline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 75 mg chlorpromazine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29306817

Group type: EXPERIMENTAL
Intervention: Electronic brief intervention (assessment of drinking and personalized feedback) and referral
Number of subjects: 123

Group type: COMPARATOR
Intervention: Referral alone (control)
Number of subjects: 123
Study: 28923720

Group type: EXPERIMENTAL
Intervention: Rosa Damascena oil (RDO)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 26038078

Group type: EXPERIMENTAL
Intervention: Light buccopalatal jiggling forces (25 g)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Heavy buccopalatal jiggling forces (225 g)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous buccal forces (positive control)
Number of subjects: 30
Study: 23672772

Group type: EXPERIMENTAL
Intervention: Adjunct extended-release quetiapine fumarate (quetiapine XR) 150 mg/d
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Adjunct extended-release quetiapine fumarate (quetiapine XR) 300 mg/d
Number of subjects: 919

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 919
Study: 21248600

Group type: EXPERIMENTAL
Intervention: Spaced Education Progress-Testing (SEPT)
Number of subjects: 2648

Group type: COMPARATOR
Intervention: Longitudinal Progress-Testing Alone (LPTA)
Number of subjects: 2648
Study: 18288327

Group type: EXPERIMENTAL
Intervention: Amalgam restorations
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Posterior occlusal surface‐years
Number of subjects: 267
Study: 17675895

Group type: EXPERIMENTAL
Intervention: Cardiovascular case management program (6 months)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 450
Study: 12873621

Group type: EXPERIMENTAL
Intervention: THC infusion and marijuana smoking
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 29
Study: 10416877

Group type: EXPERIMENTAL
Intervention: Progestational drugs
Number of subjects: 8

Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 8
Study: 9005424

Group type: EXPERIMENTAL
Intervention: Fibrosigmoidoscopy
Number of subjects: 2405
Study: 1919882

Group type: EXPERIMENTAL
Intervention: Sucrose-containing diet (Suc-Con, 10% total calories from sucrose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Traditional sucrose-free diet (Suc-Free, 2% total calories from sucrose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sucrose-containing diet (Suc-Con)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Traditional sucrose-free diet (Suc-Free)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 10
Study: 6962421

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus B.C.G.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 64
Study: 31149869

Group type: EXPERIMENTAL
Intervention: 4-week workplace cycling intervention (n = 12)
Number of subjects: 21
Study: 27741414

Group type: EXPERIMENTAL
Intervention: Topical ozone therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (systemic antibiotics only)
Number of subjects: 33
Study: 26485385

Group type: EXPERIMENTAL
Intervention: Local injection of lidocaine with 1 mg of morphine (MLA group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Local injection of lidocaine alone (LA group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (MLA and LA)
Number of subjects: 48
Study: 23569029

Group type: EXPERIMENTAL
Intervention: 9 mg Uceris®
Number of subjects: 12

Group type: COMPARATOR
Intervention: 9 mg Entocort® EC
Number of subjects: 12
Study: 22156352

Group type: EXPERIMENTAL
Intervention: Dark chocolate 30 g/day for fifteen days
Number of subjects: 32

Group type: COMPARATOR
Intervention: White chocolate 25 g/day for fifteen days (Control)
Number of subjects: 32